BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 30158411)

  • 1. [Selection of Chemotherapy Regimen on the Basis of Monitoring NLR and Soluble PD-L1 during CRC Chemotherapy].
    Muneoka K; Shirai Y; Sasaki M; Honma S; Sakata J; Kanda J; Wakabayashi H; Wakai T; Miyazaki M
    Gan To Kagaku Ryoho; 2018 Aug; 45(8):1159-1163. PubMed ID: 30158411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Change of Blood Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Metastatic Colorectal Cancer].
    Muneoka K; Shirai Y; Sasaki M; Sakata J; Kanda J; Wakabayashi H; Wakai T
    Gan To Kagaku Ryoho; 2017 Apr; 44(4):313-317. PubMed ID: 28428512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Changes in the Neutrophil-to-Lymphocyte Ratio Can Predict the Timing of Chemotherapeutic Regimen Alteration in Patients with Metastatic Colorectal Cancer].
    Muneoka K; Shirai Y; Sasaki M; Honma S; Sakata J; Kanda J; Wakabayashi H; Wakai T
    Gan To Kagaku Ryoho; 2017 Nov; 44(11):1001-1005. PubMed ID: 29138376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer.
    Park H; Bang JH; Nam AR; Eun Park J; Hua Jin M; Bang YJ; Oh DY
    Sci Rep; 2019 Jul; 9(1):11131. PubMed ID: 31366979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
    Li Y; Cui X; Yang YJ; Chen QQ; Zhong L; Zhang T; Cai RL; Miao JY; Yu SC; Zhang F
    Clin Breast Cancer; 2019 Oct; 19(5):326-332.e1. PubMed ID: 31176611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy.
    Ha H; Nam AR; Bang JH; Park JE; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
    Oncotarget; 2016 Nov; 7(47):76604-76612. PubMed ID: 27780932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer.
    Takahashi N; Iwasa S; Sasaki Y; Shoji H; Honma Y; Takashima A; Okita NT; Kato K; Hamaguchi T; Yamada Y
    J Cancer Res Clin Oncol; 2016 Aug; 142(8):1727-38. PubMed ID: 27256004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
    Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
    Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer.
    He Y; Zhang X; Zhu M; He W; Hua H; Ye F; Zhou X; Chen N; Li Y; Zhong W; Wu G; Cai H; Jiang W
    J Transl Med; 2023 Jan; 21(1):25. PubMed ID: 36639643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Tominaga T; Akiyoshi T; Yamamoto N; Taguchi S; Mori S; Nagasaki T; Fukunaga Y; Ueno M
    PLoS One; 2019; 14(2):e0212978. PubMed ID: 30807610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
    Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
    Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Change of Soluble Programmed Death Ligand 1 (sPD-L1) in Plasma of Small Cell Lung Cancer and Its Clinical Significance.
    Lu F; Dong Y; Li Q; Wang M
    Comput Math Methods Med; 2022; 2022():8375349. PubMed ID: 35126639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The level of soluble programmed death-1 in peripheral blood of patients with lung cancer and its clinical implications].
    Xing YF; Zhang ZL; Shi MH; Ma Y; Chen YJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):102-6. PubMed ID: 22455965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of soluble PD-L1 and NLR combination with 1-Year mortality in patients with COVID-19.
    Akhmaltdinova L; Mekhantseva I; Turgunova L; Kostinov M; Zhumadilova Z; Turmukhambetova A
    Int Immunopharmacol; 2024 Mar; 129():111600. PubMed ID: 38325048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
    Luo L; Shu M; Li S; Cai Y
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy.
    Kim HJ; Park S; Kim KJ; Seong J
    Radiother Oncol; 2018 Oct; 129(1):130-135. PubMed ID: 29366520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Apatinib combined with Temozolomide on levels of sPD-1 and sPD-L1 in patients with drug-resistant recurrent glioblastoma.
    Kuang RZ; Wang J; Wang YC; Tang XP
    Clinics (Sao Paulo); 2024; 79():100376. PubMed ID: 38733690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer.
    Sun J; Qiu MZ; Mei T; Gao Y; Chang B; Zhang Y; Wang FH; Li S
    Transl Cancer Res; 2020 Apr; 9(4):2434-2448. PubMed ID: 35117603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
    Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C.
    Yamagiwa S; Ishikawa T; Waguri N; Sugitani S; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Terai S
    Int J Med Sci; 2017; 14(5):403-411. PubMed ID: 28539815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.